Intervention: Dalcetrapib
Trial phase: Phase 2
SMILES: CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 48
Group description: Participants received dalcetrapib 1800 mg (six 300 mg tablets) and six placebo tablets orally daily for 10 days

Dalcetrapib: Dalcetrapib 300 mg film-coated tablets Placebo: Dalcetrapib matching placebo tablets
Eligibility criteria:
Inclusion Criteria:

Patients must satisfy all of the following criteria unless otherwise stated:

Willing and able to provide informed consent
Male or female patients > 18 years of age on the day of informed consent
Have received a confirmed diagnosis of COVID-19 (positive for SARS CoV 2), as assessed by PCR or point-of-care within 72 hours of first dose on Day 1

Have mild to moderate signs or symptoms of COVID-19 with onset within 5 days of first dose on Day 1, at least two of the following symptoms:

stuffy or runny nose
sore throat
shortness of breath
cough
fatigue
myalgia
headache
chills or shivering
feeling hot or feverish
nausea
vomiting
diarrhea
anosmia
ageusia
Outpatient with COVID-19 disease (not requiring oxygen therapy [WHO COVID-19 Clinical Improvement Ordinal Scale, score of 3])
Patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (ICF).

Exclusion Criteria:

Patients will be excluded from the study if they satisfy any of the following criteria unless otherwise stated:

Females who are pregnant (negative pregnancy test required for all women of child bearing potential at Screening) or breast-feeding
Male patients and women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not using at least one protocol specified method of contraception
Severe COVID-19 disease as defined by the WHO COVID-19 Clinical Improvement Ordinal Scale, scores of 5 (non invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation), or 7 (ventilation + additional organ support pressors, renal replacement therapy [RRT], extracorporeal membrane oxygenation [ECMO])
Expected survival less than 72 hours
Peripheral capillary oxygen saturation (SpO2) <90% while breathing room air
Treatment with other drugs thought to possibly have activity against SARS CoV 2 infection like remdesivir, favipiravir, within 7 days prior to enrollment or concurrently
History of abuse of drugs or alcohol that could interfere with adherence to study requirements as judged by the Investigator
Use of any other concurrent investigational drugs while participating in the present study
Patient requires frequent or prolonged use of systemic corticosteroids (≥20 mg of prednisone/day or equivalent for >4 weeks) or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions)
Known renal disease with an estimated glomerular filtration rate (eGFR) <50 mL/min based on local laboratory results
Patients with clinically apparent liver disease, e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis
Alanine transaminase (ALT) or aspartate transaminase (AST) >3 × upper limit of normal (ULN) or alkaline phosphatase or bilirubin levels > 2 × ULN based on local laboratory results
Co administration of clinical doses of orlistat with dalcetrapib
Inability to swallow oral medications or a gastrointestinal disorder with diarrhea (e.g., Crohn's disease) or malabsorption at Screening
Any other clinically significant medical condition or laboratory abnormality that, in the opinion of the Investigator, would jeopardize the safety of the patient or potentially impact patient compliance or the safety/efficacy observations in the study
History of an allergic reaction or hypersensitivity to the study drug or any component of the study drug formulation.